{"cik":1802768,"taxonomy":"us-gaap","tag":"Depreciation","label":"Depreciation","description":"The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.","entityName":"Royalty Pharma plc","units":{"USD":[{"start":"2023-01-01","end":"2023-12-31","val":0,"accn":"0001802768-26-000003","fy":2025,"fp":"FY","form":"10-K","filed":"2026-02-11","frame":"CY2023"},{"start":"2024-01-01","end":"2024-06-30","val":0,"accn":"0001802768-25-000095","fy":2025,"fp":"Q2","form":"10-Q","filed":"2025-08-06"},{"start":"2024-01-01","end":"2024-09-30","val":0,"accn":"0001802768-25-000114","fy":2025,"fp":"Q3","form":"10-Q","filed":"2025-11-05"},{"start":"2024-01-01","end":"2024-12-31","val":0,"accn":"0001802768-26-000003","fy":2025,"fp":"FY","form":"10-K","filed":"2026-02-11","frame":"CY2024"},{"start":"2025-01-01","end":"2025-03-31","val":0,"accn":"0001802768-26-000009","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-06","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":1379000,"accn":"0001802768-25-000095","fy":2025,"fp":"Q2","form":"10-Q","filed":"2025-08-06"},{"start":"2025-01-01","end":"2025-06-30","val":1379000,"accn":"0001802768-26-000015","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-05"},{"start":"2025-01-01","end":"2025-09-30","val":2656000,"accn":"0001802768-25-000114","fy":2025,"fp":"Q3","form":"10-Q","filed":"2025-11-05"},{"start":"2025-01-01","end":"2025-12-31","val":3852000,"accn":"0001802768-26-000003","fy":2025,"fp":"FY","form":"10-K","filed":"2026-02-11","frame":"CY2025"},{"start":"2026-01-01","end":"2026-03-31","val":1171000,"accn":"0001802768-26-000009","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-06","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":2465000,"accn":"0001802768-26-000015","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-05"}]}}